OasisLMS

1. To register, press the "Login" or "Register" button on the right.
2. Sign in with your scai.org username and password. If you don't have an account, click “Set Up Your Login.”

Acute pulmonary embolism (PE), particularly intermediate high-risk PE, remains a major clinical challenge due to the uncertainty surrounding optimal management strategies that balance efficacy and safety. Although systemic anticoagulation is standard of care, patients with intermediate high-risk PE face a substantial risk of early clinical deterioration, hemodynamic collapse, and PE-related mortality. The HI-PEITHO trial was designed to address a critical evidence gap by comparing standard anticoagulation alone with anticoagulation plus ultrasound facilitated, catheter directed, low dose thrombolysis. By evaluating a composite endpoint of PE-related mortality, cardiorespiratory decompensation, and recurrent PE within seven days, the study directly targets clinically meaningful outcomes that influence early decision making in high acuity settings.

This activity aims to bridge critical knowledge gaps in PE management by integrating the latest evidence with an expert discussion around data from the HI PEITHO trial, which will be central to updating clinical practice and improving patient outcomes.

1. Apply trial-based risk stratification criteria to identify risk PE patients who may be candidates for catheter-directed thrombolysis.
2. Differentiate levels of PE severity using clinical and imaging markers to guide escalation beyond anticoagulation.
3. Evaluate the comparative outcomes of anticoagulation alone versus ultrasound facilitated catheter directed thrombolysis based on randomized trial endpoints.